vnrx_8k.htm

0001477932-24-002772.txt : 20240513 0001477932-24-002772.hdr.sgml : 20240513 20240513161348 ACCESSION NUMBER: 0001477932-24-002772 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VOLITIONRX LTD CENTRAL INDEX KEY: 0000093314 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 911949078 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36833 FILM NUMBER: 24939210 BUSINESS ADDRESS: STREET 1: 1489 WEST WARM SPRINGS ROAD STREET 2: SUITE 110 CITY: HENDERSON STATE: NV ZIP: 89014 BUSINESS PHONE: 1 (646) 650-1351 MAIL ADDRESS: STREET 1: 1489 WEST WARM SPRINGS ROAD STREET 2: SUITE 110 CITY: HENDERSON STATE: NV ZIP: 89014 FORMER COMPANY: FORMER CONFORMED NAME: STANDARD CAPITAL CORP DATE OF NAME CHANGE: 19990812 8-K 1 vnrx_8k.htm FORM 8-K vnrx_8k.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 13, 2024

VolitionRx Limited

(Exact name of registrant as specified in its charter)

Delaware

001-36833

91-1949078

(State or other jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification Number)

1489 West Warm Springs Road, Suite 110

Henderson, Nevada

89014

(Address of Principal Executive Offices)

(Zip Code)

+1 (646) 650-1351

(Registrant’s telephone number, including area code )

Not applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol(s)		Name of Each Exchange on which Registered
Common Stock, par value $0.001 per share		VNRX		NYSE American, LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

VOLITIONRX LIMITED

Form 8-K

Current Report

Item 2.02. Results of Operations and Financial Condition.

The following information, including Exhibit 99.1, is being “furnished” in accordance with General Instruction B.2. of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

On May 13, 2024, VolitionRx Limited (the “Company”) issued a press release announcing its financial results and certain business updates for the quarter ended March 31, 2024. The Company also confirmed its conference call to be held on May 14, 2024 at 8:30 a.m. U.S. Eastern Time. Furnished herewith as Exhibit 99.1 and incorporated by reference herein is a copy of the press release.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

Number

Description

99.1

Press Release of VolitionRx Limited, dated May 13, 2024.

104

Cover Page Interactive Data File (embedded within the Inline XBRL (eXtensible Business Reporting Language) document)

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	VOLITIONRX LIMITED

Date May 13, 2024	By:	/s/ Cameron Reynolds
		Cameron Reynolds
		Chief Executive Officer & President

3

EXHIBIT INDEX

Exhibit

Number

Description

99.1

Press Release of VolitionRx Limited, dated May 13, 2024.

4

EX-99.1 2 vnrx_ex991.htm PRESS RELEASE vnrx_ex991.htm

EXHIBIT 99.1

VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update

Conference call to discuss financial and operational results scheduled for

Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time

Henderson, Nevada, May 13, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today announced financial results and a business update for the first quarter of 2024. Volition management will host a conference call tomorrow, May 14 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

A video featuring members of Volition's Executive team.

https://youtu.be/rssjucof45M

Cameron Reynolds, President and Group Chief Executive Officer of Volition said: “Throughout this quarter we have continued to work on a number of opportunities with the aim of ensuring Volition is cash flow neutral in 2025 with a mix of non-dilutive funding, revenue growth and milestone payments from out licensing, as we already achieved in our Volition Vet subsidiary, and through further cost reduction measures targeting $10 million in annualized reductions. We are making strong and necessary decisions to preserve capital in the company whilst ensuring we deliver on our vision and mission. We believe that we are now close to receiving large amounts of data for both Nu.Q^® NETs and Capture-PCR™ and consequently, subsequent to quarter end, we are taking some necessary actions to significantly reduce expenditures and cash burn as we concentrate on commercialization.

“We have invested significantly over recent years to build out our product pillars and to ensure we have robust scientific and clinical evidence to support our potential breakthrough technologies. Following our anticipated receipt, by the end of June, of a substantial amount of new clinical data, we intend to have a laser focus on commercializing these technologies.

“Our strategy is to monetize our intellectual property through licensing or other agreements, similar to our approach with Volition Vet. If successful, we believe that this strategy could provide us with meaningful milestone payments in the next 12 months, followed by ongoing payments and royalties.

“We have had a busy start to 2024 and look forward to delivering on some exciting milestones ahead, in particular publishing new data for Nu.Q^® NETs and for our potential breakthrough cancer detection method, Capture-PCR™, later this year. While the revenue ramp from Nu.Q^® Vet has taken longer than anticipated, we do expect revenues to accelerate in the second half of 2024 due to the two important recent product launches by Antech Diagnostics and Fujifilm Vet Systems.”

Financial Highlights

·
Cash and cash equivalents as of March 31, 2024, totaled approximately $11.8 million.

·
Recorded approximately $170,000 in revenue in the first quarter of 2024, up 15% over the prior year.

·
Cost reduction measures underway with a target of $10 million in annualized reductions.

·
Applied/or in the process of applying for $25 million in non-dilutive grants from funding bodies in the U.S., with a further $18 million in Europe.

1

Event: VolitionRx Limited First Quarter 2024 Earnings and Business Update Conference Call

Date: Tuesday, May 14, 2024

Time: 8:30 a.m. U.S. Eastern Time

U.S. & Canada Dial-in: 1-877-407-9716 (toll free)

U.K. Dial-in: 0 800 756 3429 (toll free)

Toll/International: 1-201-493-6779

Conference ID: 13746549

Louise Batchelor, Group Chief Marketing & Communications Officer will host the call along with Cameron Reynolds, President and Group Chief Executive Officer of Volition, Terig Hughes, Group Chief Financial Officer, Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. The call will provide an update on important events which have taken place in the first quarter of 2024 and upcoming milestones.

A live audio webcast of the conference call will also be available on the investor relations page of Volition’s corporate website at https://ir.volition.com. In addition, a telephone replay of the call will be available until May 28, 2024. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the U.S. and Canada and 1-412-317-6671 (toll) internationally. Please use replay pin number 13746549.

About Volition

Volition is a multi-national epigenetics company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.

Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients, but also improve their quality of life.

Volition's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.

2

Media Enquiries:

Louise Batchelor/Debra Daglish, Volition, mediarelations@volition.com +44 (0)7557 774620

Safe Harbor Statement

Statements in this press release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as “expects,” “anticipates,” “intends,” “plans,” “aims,” “targets,” “believes,” “seeks,” “estimates,” “optimizing,” “potential,” “goal,” “suggests,” “could,” “would,” “should,” “may,” “will” and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition’s expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, the effectiveness of Volition’s cost reduction measures, the effectiveness and availability of Volition’s blood-based diagnostic, prognostic and disease monitoring tests, Volition’s ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition’s success in securing licensing and/or distribution agreements with third parties for its products. Volition’s actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition’s failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition’s development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition’s failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition’s intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.

Nucleosomics™, Capture-PCR™ and Nu.Q^® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners. Additionally, unless otherwise specified, all references to “$” refer to the legal currency of the United States of America.

3

EX-101.SCH 3 vnrx-20240513.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 vnrx-20240513_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity File Number Entity Incorporation State Country Code Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Security 12b Title Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 5 vnrx-20240513_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 vnrx-20240513_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 vnrx-20240513_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE GRAPHIC 8 vnrx_ex991img1.jpg begin 644 vnrx_ex991img1.jpg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htm IDEA: XBRL DOCUMENT

Cover	May 13, 2024
Cover [Abstract]
Entity Registrant Name	VolitionRx Limited
Entity Central Index Key	0000093314
Document Type	8-K
Amendment Flag	false
Entity Emerging Growth Company	false
Document Period End Date	May 13, 2024
Entity File Number	001-36833
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	91-1949078
Entity Address Address Line 1	1489 West Warm Springs Road
Entity Address Address Line 2	Suite 110
Entity Address City Or Town	Henderson
Entity Address State Or Province	NV
Entity Address Postal Zip Code	89014
City Area Code	646
Local Phone Number	650-1351
Security 12b Title	Common Stock, par value $0.001
Trading Symbol	VNRX
Security Exchange Name	NYSE
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false

EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 15 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 23 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://vnrx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports vnrx-20240513.xsd vnrx-20240513_cal.xml vnrx-20240513_def.xml vnrx-20240513_lab.xml vnrx-20240513_pre.xml vnrx_8k.htm http://xbrl.sec.gov/dei/2023 true true JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vnrx_8k.htm": { "nsprefix": "vnrx", "nsuri": "http://vnrx.com/20240513", "dts": { "schema": { "local": [ "vnrx-20240513.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] }, "calculationLink": { "local": [ "vnrx-20240513_cal.xml" ] }, "definitionLink": { "local": [ "vnrx-20240513_def.xml" ] }, "labelLink": { "local": [ "vnrx-20240513_lab.xml" ] }, "presentationLink": { "local": [ "vnrx-20240513_pre.xml" ] }, "inline": { "local": [ "vnrx_8k.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://vnrx.com/role/Cover", "longName": "000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "From2024-05-13to2024-05-13", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "From2024-05-13to2024-05-13", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vnrx_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 1", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Address Line 2", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address City Or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address State Or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://vnrx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001477932-24-002772-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-24-002772-xbrl.zip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vnrx_8k_htm.xml IDEA: XBRL DOCUMENT 0000093314 2024-05-13 2024-05-13 iso4217:USD shares iso4217:USD shares 0000093314 false 8-K 2024-05-13 VolitionRx Limited DE 001-36833 91-1949078 1489 West Warm Springs Road Suite 110 Henderson NV 89014 646 650-1351 false false false false Common Stock, par value $0.001 VNRX NYSE false

	·	Cash and cash equivalents as of March 31, 2024, totaled approximately $11.8 million.
	·	Recorded approximately $170,000 in revenue in the first quarter of 2024, up 15% over the prior year.
	·	Cost reduction measures underway with a target of $10 million in annualized reductions.
	·	Applied/or in the process of applying for $25 million in non-dilutive grants from funding bodies in the U.S., with a further $18 million in Europe.